Thursday, 22 August 2019

Astellas gets FDA nod for kidney transplant drug

22 July 2013 | News | By BioSpectrum Bureau

Astellas gets FDA nod for kidney transplant drug

Astellas gets FDA nod for kidney transplant drug

Singapore: Japan-based Astellas Pharma has received US FDA approval for Astagraf XL (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction.

"Each transplant recipient is different and requires a personalized treatment approach. The approval of Astagraf XL marks an important milestone in post-transplant care as it provides physicians with a new treatment option for kidney transplant recipients," said Dr Sef Kurstjens, chief medical officer, Astellas Pharma, US. "Astellas is pleased to continue our more than 20-year commitment to the field of transplant immunology."

Astagraf XL is the first once-daily oral tacrolimus formulation available in the US for kidney transplant recipients. It offers a potentially promising treatment option for appropriate kidney transplant recipients as a core component of an immunosuppressive regimen for the prophylaxis of organ rejection.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Will APAC lead the way for innovation in the field of precision medicine?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls